Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inspiring Results For Phase III Disease-Modifying Cystic Fibrosis Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Inspire Pharmaceuticals' denufosol showed improvement in FEV1 versus placebo over 24 weeks.

You may also be interested in...



Stockwatch: The TIGER That Came To Lilly

The reasons behind Lilly's latest clinical failure had much less to do with the indication and more to do with repeating the past mistakes of Inspire and Sunesis. Unfortunately, that same die has already been cast for the trials of Biogen and Ophthotech that are due to report imminently.

Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate

Open-label safety extension of earlier Phase III study shows progressive improvement from baseline over time.

Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate

Open-label safety extension of earlier Phase III study shows progressive improvement from baseline over time.

Related Content

Topics

UsernamePublicRestriction

Register

PS068040

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel